Advertisement

ZTS

Zoetis Inc.

Healthcare · USD

Set alert

Price alert · ZTS

All alert types
79.72 USD +1.45 +1.85%
As of Oct 30, 2026 Extended hours 79.29 -0.54%
Bid
79.69 × 200
Ask
79.72 × 100
79.22 Day range 80.60
69.10 52-week range 144.35
YTD
-36.64%
1 year
-44.68%
Open
79.84
Prev close
78.27
Mkt cap
32.94B
Vol
4.12M
Avg vol
5.00M
EPS
6.08
P/E
13.11
Div yield
2.69%
More statistics
Low
79.22
High
80.60
Forward P/E
12.44
Beta
0.74
Short ratio
3.99
Inst. own
100.27%
Dividend
2.12
Ex-div date
Oct 29, 2026
Earnings
Nov 5, 2026
50-d avg
74.95
200-d avg
93.76
1y target
88.38

5D chart

Chart tools
Interval
ZTS five-day price chart77.078.179.180.281.2Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
32.94B
Enterprise value
40.14B
Trailing P/E
13.11
Forward P/E
12.44
PEG ratio
14.67
Price / sales
3.46
Price / book
10.49
EPS (TTM)
6.08
Beta
0.74
Dividend yield
2.69%
Payout ratio
33.88%
Profit margin
27.68%
Revenue (TTM)
9.53B
Revenue growth
-0.20%
Free cash flow
2.02B
Total cash
1.68B
Total debt
9.26B
Return on equity
64.91%
Shares outstanding
413.22M
Short % of float
4.80%
50-day average
74.95
200-day average
93.76

Analyst view

Consensus: hold

Hold
Price target (mean) 88.38 +10.9% upside
Target (low)
74.00
Target (mean)
88.38
Target (high)
115.00
Ratings (0m) 16 5 buy · 11 hold · 0 sell
  • Strong buy3
  • Buy2
  • Hold11
  • Sell0
  • Strong sell0

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate 1.51.

Earnings history

Financials — quick view

All financials
ZTS Revenue — quarterly 2.47B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ZTS Net income — quarterly 691.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ZTS EPS — quarterly 1.65
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ZTS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 20261.51———
Aug 6, 2026Jun 30, 20261.851.87+0.02+1.08%
May 7, 2026Mar 31, 20261.601.53-0.07-4.38%
Feb 12, 2026Dec 31, 20251.401.48+0.08+5.71%
Nov 4, 2025Sep 30, 20251.621.70+0.08+4.94%
Aug 5, 2025Jun 30, 20251.621.76+0.14+8.64%

Upgrades / downgrades

ZTS analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026Morgan StanleymainOverweightOverweight
Oct 27, 2026UBSmainNeutralNeutral
Oct 20, 2026JefferiesdownBuyHold
Oct 16, 2026Goldman Sachsinit—Neutral
Aug 25, 2026TD CowenmainBuyBuy
Aug 20, 2026StifelmainHoldHold

About Zoetis Inc.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
zoetis.com

News

Your note

Sign in to keep a note on ZTS — it syncs with the Stock Master app.

Insider holders

ZTS insider holders
InsiderRelationLatest transactionDateShares held
BISARO PAUL M.DirectorPurchaseMay 12, 202627,862
D AMELIO FRANK ADirectorStock GiftAug 6, 202621,458
JOSEPH WETTENYChief Financial OfficerConversion of Exercise of derivative securityFeb 5, 202620,766
LAGANO ROXANNEOfficerConversion of Exercise of derivative securityFeb 18, 202616,465
MCCALLISTER MICHAEL BDirectorStock GiftJun 9, 202631,893
NORDEN GREGORYDirectorStock GiftMar 8, 202618,167

Institution ownership

ZTS institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.54%39,430,1813.14BJun 29, 2026
Vanguard Capital Management LLC6.30%26,027,9842.07BJun 29, 2026
Vanguard Portfolio Management LLC5.77%23,860,4451.90BJun 29, 2026
State Street Corporation4.76%19,667,7231.57BJun 29, 2026
State Farm Mutual Automobile Insurance Co3.85%15,892,9031.27BJun 29, 2026
Geode Capital Management, LLC3.22%13,289,6221.06BJun 29, 2026

Fund ownership

ZTS fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.90%11,982,269955.11MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.63%10,862,724865.87MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund1.98%8,175,936651.70MJun 29, 2026
VANGUARD FENWAY FUNDS-Vanguard Equity Income Fund1.48%6,106,220486.73MJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%5,506,516438.92MSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.32%5,441,955433.78MAug 30, 2026
Advertisement